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Comorbidities and their impact on outcome in patients with ported in various registries for patients with end-stage
end-stage renal disease. End-stage renal disease is associated renal disease range from 10% to over 20% [1–3]. Fur-
with an increased mortality compared to age-matched controls. thermore, as advances have been made in renal replace-Increasing age, diabetes, cardiovascular disease and poor nutri-
ment therapy, the patient population initiating treatmenttion are the most important co-existing conditions that predict
has become older and often has a number of comorbidworse outcomes for patients with end-stage renal disease. Of
the cardiovascular conditions that are associated with higher conditions that become the major determinants of sur-
mortalities, ischemic heart disease and left ventricular hyper- vival. Improvements in outcome for patients with ESRD
trophy have a high prevalence amongst the predialysis and will depend in part on improvements in the renal replace-dialysis population. There are multiple risk factors associated
ment therapy itself, but also on the better understandingwith uremia that predispose to these conditions. Congestive
and management of those conditions which coexist andheart failure is also a strong predictor of poor outcome and
often coexists with hypertension and ischemic heart disease. become the primary determinants of outcome. This arti-
Although hypertension in the general population is associated cle will review several of the major comorbidities, their
with higher mortalities, in dialysis patients hypotension is a prevalence, their impact on outcome, and their etiolo-more accurate predictor of high mortality rates. Diabetes is
gies, which may give insight into treatment strategies.now the most common cause of end-stage renal disease in
In 1982 Hutchinson et al [4] reported that the risk ofmany parts of the world. It has a strong negative impact on
survival and is associated with the presence of vascular disease. death for a patient initiating renal replacement therapy
Similarly, increasing age in the uremic population is associated doubled with each decade, with the coexistence of diabe-
with a high frequency of hypertension and vascular disease. tes and with the occurrence of an episode of congestivePoor nutritional status, as indicated by a low serum albumin
heart failure. Although additional insights have beenor subjective global assessment is a strong predictor of high
made with regard to understanding pathogenesis, age,mortality. This may in part indicate the coexistence of a chronic
inflammatory state. The most important predictors of poor diabetes and heart disease, together with nutritional sta-
outcome in end-stage renal disease are increasing age, cardio- tus, remain the most important predictors of outcome for
vascular disease, diabetes and poor nutrition as reflected by this patient population. Of these factors, cardiovascular
hypoalbuminemia. Future studies need to be initiated which
disease, diabetic management, and nutritional status arewill assess the impact of interventions which modify directly
potentially modifiable. Thus, it is important to concen-these co-morbidities.
trate our attention on these issues. There are additional
conditions that have a strong impact on outcome, such
as AIDS or malignancy, which affect a small percentageRenal replacement therapy has offered millions of pa-
of the ESRD population. The management of AIDStients an opportunity to prolong their lives. The success
patients is a good example of how improvement in theof the therapy has been undeniable, and outcomes con-
overall care of these patients has resulted in improve-tinue to improve. In spite of these advances, patients
ments in their outcome on dialysis [5].with end-stage renal disease (ESRD) have a significantly
reduced life expectancy compared to age-, gender-, and
race-matched populations. In the United States, the CARDIOVASCULAR DISEASE
mean expected life span for patients beginning dialysis at
The most important cardiovascular abnormalitiesage 40 is 9.3 years, and is 4.3 years for patients beginning
in ESRD are ischemic heart disease, left ventricular hy-dialysis at the age of 59 [1]. Annual mortality rates re-
pertrophy, congestive heart failure, hypertension, and
peripheral vascular disease. Other conditions such as
Key words: comorbidities, outcomes, ESRD. arrhythmias, vascular disease, and infiltrative disease
represent a smaller clinical problem. 2000 by the International Society of Nephrology
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Ischemic heart disease as compared to those without cardiovascular disease
(66.3%), who accounted for only 5.8% of the deaths. InDiseases that cause ESRD often constitute a risk fac-
a cohort of 433 patients from the Royal Victoria Hospitaltor for ischemic heart disease, with diabetes, hyperten-
in Montreal, Quebec, and the Health Sciences Centresion, and peripheral vascular disease causing renal artery
in St. John’s, Newfoundland, the existence of ischemicstenosis being the most common examples. However,
heart disease at the initiation of dialysis had a significantthe onset of renal failure also adds new cardiovascular
negative impact on survival [9]. At 5 years, the survivalrisk factors to these patients [6]. Lipoprotein abnormali-
rate in those with ischemic heart disease was approxi-ties including low levels of high density lipoprotein
mately 22% compared to those without ischemic heart(HDL), hypertriglyceridemia, and elevated low density
disease, in whom the survival rate was almost 50%. Usinglipoprotein (LDL) cholesterol abnormalities and Lp(a)
a Cox proportional hazards model, ischemic heart dis-are frequent. Homocysteine levels are virtually always
ease increased the odds ratio of death to 1.48 (P , 0.001).significantly elevated and often are resistant to vitamin
However, ischemic heart disease also predicted a greatersupplementation. Chronic inflammation, insulin resis-
likelihood of an episode of congestive heart failure. Us-tance, elevated calcium, phosphate products and oxida-
ing the same Cox proportional hazards model in whichtive stress all constitute additional risk factors which are
heart failure is entered into the analysis, ischemic heartbrought on by the condition of uremia. Conventional
disease did not add further risk to the outcome for therisk factors such as family history and smoking add to
patients. In that analysis it appears that the impact ofthe list of atherosclerotic risk factors. Thus, it is not
ischemic heart disease is in its contribution to causingsurprising that the prevalence of ischemic heart disease
heart failure, which then becomes a much more powerfulis very high within the dialysis population.
predictor of death.In data from the U.S. Case Mix study [7], 40% of
In summary, patients with ESRD have multiple riskhemodialysis and peritoneal dialysis patients were re-
factors for ischemic heart disease and the same systemicported to have clinical coronary artery disease. This may
diseases that predisposed to renal failure also represent
represent an underestimate of the incidence since many
risk with respect to ischemic heart disease. The existence
patients with congestive heart failure may have as their of ischemic heart disease in this patient population pre-
underlying etiology coronary ischemic heart disease disposes to a worse outcome after initiating renal re-
which has not presented clinically as such. In a recent placement therapy.
survey at the Royal Victoria Hospital in Montreal, 60%
of the dialysis population patients prevalent on May 15th, Left ventricular hypertrophy
1998 had a diagnosis of ischemic heart disease. In the Framingham studies, left ventricular hypertro-
In the 1998 Canadian Registry [3], ischemic heart dis- phy was found to be an independent risk factor for death
ease was present in 23.1 % of the diabetic and 5.2% of in the general population [10]. The most important deter-
the nondiabetic patients starting analysis who were un- minant of left ventricular hypertrophy (LVH) in the non-
der the age of 45 years. In those over the age of 45 years, uremic patient is hypertension. There are similarities in
that increases to 56.6% of the diabetics and 45.8% of the renal failure population.
the nondiabetics. In this report, ischemic heart disease LVH is extremely common in the uremic population.
was defined as the presence of angina or a history of In a report by Levin et al [11], the prevalence of LVH
myocardial infarction. In chronic renal insufficiency, i.e., was 26.7% of patients with a creatinine clearance .50
predialysis, the incidence of ischemic heart disease is mL/min, 30.8% in those with clearance between 25 and
less certain, but in a prospective study of 422 patients 49 mL/min, and 45.2% in those with clearance ,25 mL/
followed in Canada, 23% had had a coronary artery min. LVH has been reported to be present in up to 75%
bypass, angioplasty, acute myocardial infarction, or an- of patients on hemodialysis and peritoneal dialysis. At
gina (unpublished data). In the Canadian hemodialysis the initiation of dialysis in a Canadian study, 39.4% of
morbidity study [8], 33.7% of the patients on dialysis the patients had concentric LVH [12]. Risk factors for the
had cardiovascular disease, of which the vast majority development of LVH have consistently been shown to
had ischemic heart disease. Thus, it is clear that patients include age and blood pressure [13, 14]. Anemia has
with uremia have an extraordinarily high coexistence of often been shown to be a risk factor [15], and its correc-
ischemic heart disease. tion is associated with regression of LVH. Other factors,
The impact of the coexistence of ischemic heart dis- including the presence of fistulas, hyperparathyroidism,
ease on survival is important but is often confounded and certain antihypertensives, have been variably re-
by the coexistence of left ventricular hypertrophy and ported as an association.
congestive heart failure. In the Canadian morbidity study As is true in the non-uremic population, LVH is a
[8], cardiovascular disease existed in 33.7% of the pa- risk factor for mortality in the dialysis population. In
comparing the upper and lower quintile for left ventricu-tients, yet this group accounted for 16.2% of the deaths
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lar mass index in a dialysis population, the adjusted rela- but it underlines the potential importance of aggressive
tive risk for overall mortality was 2.9 and for cardiac management of volume status in improving outcomes
death was 2.7 [16]. Furthermore, left ventricular abnor- for our patient population.
malities were associated with an increase in de novo
ischemic heart disease and heart failure [9]. Peripheral vascular disease
In summary, LVH is common in patients initiating Peripheral vascular disease is an important cause of
dialysis and becomes more common once the patients morbidity in ESRD patients. The coexistence of ischemic
initiate renal replacement therapy. It is an independent heart disease and diabetes with peripheral disease is fre-
risk factor for death as well as a predisposing factor
quent. For example, in the U.S. study of high targetfor the development of heart failure and ischemic heart
hematocrits for patients with clinical cardiac disease,disease.
38% of the patients had peripheral vascular disease [20].
In the Canadian Renal Failure Registry in 1998 [3], inHypertension
patients under the age of 45 years, 14.4% of the diabeticsHypertension can be both a cause of renal failure
and 1% of the non-diabetics had peripheral vascularand a frequent complication of renal insufficiency. With
disease at the initiation of dialysis. In those over the agerespect to the impact of hypertension on outcome for
of 45 years those percentages increased to 28.8% andrenal failure patients, the data is somewhat paradoxical.
15.5% for the diabetics and non-diabetics, respectively.Hypertension is a predisposing factor for the develop-
ment of left ventricular hypertrophy which is a risk factor In 1998, non-cardiac vascular disease was reported as a
for both death and the development of congestive heart cause of death in 7% of all patients over the age of 45
failure [17]. These latter two effects have a negative years in Canada and in 8.2% of all patients under the
impact on outcomes. age of 45.
More recently, however, a number of studies have
demonstrated that low blood pressure is an important
risk factor for higher mortality in dialysis patients [18, DIABETES
19]. In order to reconcile these two sets of observations, Diabetes has emerged as the leading cause of ESRD
one can develop a hypothesis that the existence of hyper- in many parts of the world. In all registries, the coexis-
tension predisposes to both left ventricular hypertrophy
tence of diabetes is noted to have a negative impact onand ischemic heart disease, which in turn predispose to
survival at all ages [2, 3]. The majority of the diabeticsheart failure. As the heart failure advances and pump
included in such registries are type 2 diabetics, but thefailure follows, blood pressures might be expected to
analyses are usually a mix of both type 1 and type 2fall. Thus, the poor survival with low blood pressure may
diabetics.be a marker for cardiac failure rather than an indication
Diabetes has a particularly important impact on vascu-that low blood pressure per se is an independent risk
lar disease. From the Canadian Renal Failure Registryfactor for mortality.
[3], diabetics under the age of 45 have a marked increase
Congestive heart failure in incidence of angina, myocardial infarction, cerebral
As originally described by Hutchinson [4], the occur- vascular accident and peripheral vascular disease, as
rence of congestive heart failure has been demonstrated shown in Table 1. In patients over the age of 45, the
to have a negative impact on outcomes in patients with difference between diabetics and non-diabetics is not as
end-stage renal disease. In the U.S. Case Mix adequacy great as in the younger group but the prevalence of all
study, 40% of patients on hemo and peritoneal dialysis of these vascular co-morbidities is significantly higher.
had clinical congestive heart failure [7]. In the Canadian This translates into cardiovascular mortality rates for
study, 25.1% of the patients had LV dilation on echocar- diabetic dialysis patients that exceed their age and gender
diography and a further 24.1% developed de novo car- matched comparison groups in all age groups. From the
diac failure in follow-up [17]. Heart failure gave an odds
USRDS, diabetics over the age of 85 have an annualratio of 1.93 of death using a Cox proportional hazard
cardiovascular mortality rate in excess of 25%. In themodel. In the USRDS, cardiac failure independently pre-
Canadian morbidity study [8], diabetes was present indicted mortality in a cohort of 3,399 patients starting
18.6% of the study group and yet accounted for 9.8%hemodialysis (relative risk 1.26). Finally, the observation
of the deaths compared to 81.4% of the population whichthat patients on peritoneal dialysis who are high trans-
is non-diabetic and accounted for only 9.2% of all deaths.porters have a higher mortality rate despite better clear-
Thus, diabetes is a common and important risk factorances has been interpreted as being an indication of
for death, and in particular enhances the cardiovascularchronic fluid overload and perhaps subclinical heart fail-
ure. No direct evidence for this linkage has been made, risk of the patient. Management of this important group
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Table 1. Comorbidity by age and diabetic status, Canada 1988–1996*
Diabetic Non-diabetic Diabetic Non-diabetic
,45 yrs ,45 yrs .45 yrs .45 yrs
Angina 13.0 3.1 31.8 26.0
Myocardial infarction 10.1 2.1 24.8 19.8
Peripheral vascular disease 14.8 1.0 28.5 15.8
Hypertension 76.8 55.9 78.4 67.5
* All values are given as percent of total. Table is reproduced with permission from [3].
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